Abstract
Although numerous studies have been conducted on ginger extracts and fractions, the data on the pharmacological activity of single constituents of Zingiber officinale are still insufficient. To assess the antidementia properties of the plant, a thin layer chromatography (TLC)-based bioautography acetylcholinesterase inhibitory assay was performed on the Zingiber officinale diethyl ether extract. It led to the recognition of three active inhibitors among volatile constituents of the plant: ar-curcumene (A), α-sesquiphellandrene (B) and a-zingiberene (C). The identification of the components was possible thanks to the application of a TLC–HPLC-MS interface analysis of active zones and the GC-MS qualitative analysis of the tested samples. Based on the obtained results, the influence of several extraction techniques (hydrodistillation—HD, pressurized liquid extraction or accelerated solvent extraction—ASE, shaking maceration–SM, supercritical fluid extraction–SFE, and ultrasound-assisted extraction—UAE) on the recovery of the active metabolites from plant material was assessed to deliver enriched extracts. As a result, HD and SFE, were found to be the most efficient methods to recover the volatile components and the concentrations of A, B, and C reached 0.51 ± 0.025, 0.77 ± 0.045, and 1.67 ± 0.11 percent, respectively. Only HD and SFE were found to recover monoterpene hydrocarbons from the plant matrix. The remaining techniques provided extracts rich in more complex constituents, like sesquiterpenes.
Highlights
IntroductionThe occurrence of dementia and neurodegenerative diseases (like Alzheimer’s disease) is increasing, especially among the older population
The occurrence of dementia and neurodegenerative diseases is increasing, especially among the older population
2-naphtyl acetate plays a role of a substrate and is added to the mobile phase developing the thin layer chromatography (TLC)
Summary
The occurrence of dementia and neurodegenerative diseases (like Alzheimer’s disease) is increasing, especially among the older population. It is estimated, that by 2050 ca. 115.4 million people will be affected by the progression of the disease. This fact has a significant impact on the budget of healthcare and social care around the world, especially because there is no effective drug against. The currently available medications can slow down the progression of dementia, but not to treat it. Based on the above information, the search for new potential drug candidates that retard the progression of memory impairment is of the highest importance [1,2].
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
